Anti-β2-glycoprotein I antibodies recognizing platelet factor 4–heparin complex in antiphospholipid syndrome in patient substantiated with mouse Model
✍ Scribed by Mustapha Bourhim; Luc Darnige; Cécile Legallais; Josiane Arvieux; Ramiro Cevallos; Claire Pouplard; Mookambeswaran A. Vijayalakshmi
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 101 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0952-3499
- DOI
- 10.1002/jmr.619
No coin nor oath required. For personal study only.
✦ Synopsis
The antiphospholipid syndrome is defined by the presence of antiphospholipid antibodies associated with arterial and/or venous thrombosis, and recurrent abortion accompanied often by thrombocytopenia. These antibodies are heterogeneous and react against phospholipid-binding proteins such as beta2-glycoprotein I (beta2GPI) and prothrombin. The recognition of anti-beta2-glycoprotein I (anti-beta2GPI) by platelet factor 4-heparin complex (PF4-Hc) has been previously evoked and partially confirmed by the present inhibition studies. Further, the anti-beta2-glycoprotein I antibodies were purified from a patient with primary antiphospholipid syndrome using Affi-gel-10-beta2GPI immunoaffinity chromatography. The purified anti-beta2GPI IgM as well as patient serum equally recognized PF4-Hc in ELISA mode. In order to substantiate this data and to better understand we studied an animal model using mouse active immunization with the purified human anti-beta2GPI. The mice showed a significant decrease in their platelet count. In addition the ELISA responses of the immunized mice sera were positive against both beta2GPI and PF4-Hc, substantiating the double recognition. Despite many previous reported animal model studies, this is the first time we have shown the specific recognition of anti-beta2GPI antibodies by PF4-Hc, the results in the induced mice correlating the data observed with some patients.
📜 SIMILAR VOLUMES